← GYRE THERAPEUTICS, INC. GYRE
Market Price
$6.70
Market Cap
$630.68M
P/E Ratio
335.00
Revenue (FY 2025)
↑10.2% YoY
$116.59M
3-Yr CAGR: 427.6%
Net Income
↓-44.8% YoY
$9.88M
Net Margin: 8.5%
Free Cash Flow
↑97.0% YoY
-$180.00K
FCF Yield: -0.03%
EPS (Diluted)
↓-60.0% YoY
$0.02
Basic: $0.06
Return on Equity
Efficiency
9.3%
ROA: 9.7%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (GYRE)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2018: Revenue YoY (-99.4%) is identical to Gross Profit YoY (-99.4%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
- FY 2019: Revenue YoY (+35650.0%) is identical to Gross Profit YoY (+35650.0%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
- FY 2020: Revenue YoY (+876.6%) is identical to Gross Profit YoY (+876.6%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
- FY 2021: Revenue YoY (-65.0%) is identical to Gross Profit YoY (-65.0%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
- FY 2022: Revenue YoY (-89.2%) is identical to Gross Profit YoY (-89.2%). Verify the underlying Revenue and Gross Profit values for FY 2022 and FY 2021.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | — | — | — | $-16.9M | — | $-21.75 | — | $-18.5M | $-18.9M | — |
| FY 2017 | $1.0M | — | $0.6M | $-21.6M | -27.2% | — | — | $-19.9M | $-20.0M | -5.4% |
| FY 2018 | $0.0M | -99.4% | $0.0M | $-30.1M | -39.4% | — | — | $-28.6M | $-28.9M | -44.9% |
| FY 2019 | $2.1M | +35,650.0% | $1.2M | $-55.2M | -83.6% | — | — | $-43.6M | $-43.7M | -51.0% |
| FY 2020 | $20.9M | +876.6% | $11.8M | $-56.2M | -1.9% | — | — | $-55.0M | $-55.3M | -26.6% |
| FY 2021 | $7.3M | -65.0% | $4.1M | $-87.9M | -56.4% | — | — | $-83.8M | $-84.6M | -52.9% |
| FY 2022 | $0.8M | -89.2% | $0.4M | $-8.2M | +90.6% | $-0.26 | — | $-33.1M | $-33.8M | +60.0% |
| FY 2023 | $113.5M | +14,188.4% | $108.8M | $-85.5M | -937.1% | $-1.41 | -442.3% | $25.9M | $17.4M | +151.4% |
| FY 2024 | $105.8M | -6.8% | $101.9M | $17.9M | +120.9% | $0.05 | +103.5% | $-3.6M | $-6.0M | -134.3% |
| FY 2025 | $116.6M | +10.2% | $111.2M | $9.9M | -44.8% | $0.02 | -60.0% | $1.0M | $-0.2M | +97.0% |
Valuation
Market Price
$6.70
Market Cap
$630.68M
Enterprise Value
N/A
P/E Ratio
335.00
P/B Ratio
6.13
FCF Yield
-0.03%
Dividend Yield
3.58%
Shares Outstanding
Profitability & Margins
Gross Margin
95.35%
Operating Margin
9.85%
Net Margin
8.47%
Return on Equity (ROE)
9.32%
Return on Assets (ROA)
9.65%
Asset Turnover
1.14x
Revenue 3-Yr CAGR
427.57%
Financial Health & Liquidity
Current Ratio
5.60
Cash Ratio
2.03
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$37.07M
Total Debt
N/A
Book Value / Share
$1.09
Cash Flow Efficiency
Operating Cash Flow
$1.01M
Capital Expenditures (CapEx)
$1.19M
Free Cash Flow
-$180.00K
OCF / Revenue
0.87%
FCF / Revenue
-0.15%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$0.02
EPS (Basic)
$0.06
Dividends / Share
$0.24
Book Value / Share
$1.09
EPS YoY Growth
-60.00%
Balance Sheet (FY 2025)
Total Assets
$102.37M
Total Liabilities
$18.29M
Stockholders' Equity
$106.03M
Current Assets
$102.37M
Current Liabilities
$18.29M